Low‐density lipoprotein receptor activity in Epstein‐Barr virus‐transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene
- 1 January 2006
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 66 (4) , 317-328
- https://doi.org/10.1080/00365510600672775
Abstract
Missense mutations in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene have been found to cause autosomal dominant hypercholesterolemia. The objective of this study was to investigate possible mechanisms by which mutation D374Y in the PCSK9 gene causes hypercholesterolemia. Binding and internalization of low-density lipoprotein LDL in Epstein-Barr virus (EBV)-transformed lymphocytes from D374Y heterozygotes were examined. The autocatalytic activity of the D374Y mutant was studied in transiently transfected HEK293 cells. As determined by Western blot analysis of transiently transfected HEK293 cells, the autocatalytic activity of the D374Y mutant was approximately 95% of the wild-type. Levels of PCSK9 mRNA in EBV-transformed lymphocytes from D374Y heterozygotes and normal controls were similar and less than 1/1000 of the level in HepG2 cells. The amount of cell surface LDL receptors (LDLRs) in EBV-transformed lymphocytes from five D374Y heterozygotes was non-significantly increased by 17% compared with the amount in normal controls. LDLR-dependent binding and internalization of LDL in EBV-transformed lymphocytes from D374Y heterozygotes were non-significantly reduced by 11% and 12%, respectively, compared to the corresponding values in normal controls. LDLR-mediated endocytosis of LDL is not reduced in EBV-transformed lymphocytes from D374Y heterozygotes. Because of the extremely low levels of PCSK9 mRNA in EBV-transformed lymphocytes, it is possible that the LDLR-dependent endocytosis of LDL could be more severely affected in hepatocytes from D374Y heterozygotes than in EBV-transformed lymphocytes.Keywords
This publication has 24 references indexed in Scilit:
- Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemiaHuman Molecular Genetics, 2005
- No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genesAtherosclerosis, 2004
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences, 2004
- Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemiaClinical Genetics, 2004
- A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigreeHuman Genetics, 2004
- Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed miceJournal of Lipid Research, 2003
- Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genesProceedings of the National Academy of Sciences, 2003
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003
- The Molecular Mechanism for the Genetic Disorder Familial Defective Apolipoprotein B100Journal of Biological Chemistry, 2001